Journal of atherosclerosis and thrombosis最新文献

{"title":"A Case of Familial Chylomicronemia Syndrome Caused by a Novel Homozygous GPIHBP1 Mutation Successfully Treated with the Selective PPARα Modulator Pemafibrate.","authors":"Tomoko Otsuki, Yumi Chung, Yusuke Kawachi, Shiho Komuku, Masayuki Yamanishi, Toru Takano, Atsuhiro Yamaguchi, Hiroyuki Hanada, Daisaku Masuda, Kazuya Miyashita, Shizuya Yamashita","doi":"10.5551/jat.66218","DOIUrl":"10.5551/jat.66218","url":null,"abstract":"<p><strong>Aim: </strong>Familial chylomicronemia syndrome (FCS) is a rare disorder characterized by the accumulation of chylomicrons in the circulation due to genetic defects or autoantibodies affecting lipoprotein lipase (LPL), the key enzyme responsible for the metabolism of chylomicrons and very-low-density lipoproteins (VLDL), or its associated proteins, including apolipoprotein (apo) C-II, apoA-V, glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1), and lipase maturation factor 1 (LMF1). This condition is associated with markedly elevated serum triglyceride (TG) levels and, in severe cases, recurrent episodes of pancreatitis and eruptive xanthomas. Among these etiologies, genetic deficiency of GPIHBP1 is exceedingly rare. We aimed to clarify the clinical and genetic basis and treatment strategies of a patient with GPIHBP1 deficiency.</p><p><strong>Methods: </strong>A 47-year-old woman with a childhood diagnosis of FCS presented with severe epigastric pain and was admitted to Rinku General Medical Center for emergency management of acute pancreatitis secondary to severe chylomicronemia. She had a history of severe hypertriglyceridemia complicated by pancreatitis during her first pregnancy and extreme hypertriglyceridemia exceeding 6,000 mg/dL during her second pregnancy without the development of pancreatitis. DNA sequence analysis was performed as a clinical diagnostic test and outsourced to KUBIX Inc. (Hakusan, Ishikawa, Japan).</p><p><strong>Results: </strong>Laboratory evaluation revealed marked hypertriglyceridemia (1,262 mg/dL) with a type V hyperlipoproteinemia pattern. Serum preheparin LPL mass was markedly reduced, and circulating GPIHBP1 was undetectable. Genetic analysis identified a novel homozygous frameshift mutation in the GPIHBP1 gene (NM_178172.4:c.20del [p.Val7AlafsTer73]), which has not been previously reported in public databases. No pathogenic variants were detected in other LPL-related genes. Acute pancreatitis improved rapidly with fasting and intravenous fluid therapy. Strict dietary fat restriction, followed by the addition of the selective PPARα modulator pemafibrate, successfully maintained TG levels below 500 mg/dL during follow-up.</p><p><strong>Conclusion: </strong>We report an extremely rare case of FCS caused by a novel homozygous mutation in the GPIHBP1 gene, in which pregnancy served as a major trigger for severe hypertriglyceridemia. Early diagnosis and strict lipid control are essential to prevent recurrent pancreatitis in patients with GPIHBP1 deficiency.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"1194-1204"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148271583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Plasma Omega-3 and Omega-6 Fatty Acid Levels and Atrial Fibrillation: A Large-Scale, Real-World Retrospective Study in Japan.","authors":"Naotake Yanagisawa, Kazutoshi Fujibayashi, Tetsuro Miyazaki, Hiroyuki Daida","doi":"10.5551/jat.66117","DOIUrl":"10.5551/jat.66117","url":null,"abstract":"<p><strong>Aim: </strong>The relationship between omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) and atrial fibrillation (AF) remains unclear. This retrospective study aimed to investigate the association between plasma levels of omega-3 PUFAs (eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA]) and omega-6 PUFAs (arachidonic acid [AA] and dihomo-γ-linolenic acid [DGLA]) and the prevalence of AF.</p><p><strong>Methods: </strong>After excluding patients who were prescribed icosapent ethyl (IPE) or were younger than 40 years, data from 9,178 patients at Juntendo University Hospital with plasma EPA, DHA, AA, and DGLA measurements obtained between April 2017 and January 2021 were analyzed. The plasma PUFA levels were divided into quartiles, with the lowest quartile used as the reference. Multivariable logistic regression and restricted cubic spline analyses were performed to assess the association between the PUFA levels and AF.</p><p><strong>Results: </strong>The median age was 69 years (interquartile range [IQR], 59-77 years), and 60.6% of the participants were male. AF was diagnosed in 908 (9.9%) patients. After adjusting for age, sex, and body mass index (BMI), higher plasma levels of EPA, DHA, EPA+DHA, AA, and DGLA were significantly associated with a lower risk of AF (all P＜0.001). In contrast, no significant associations were observed between the PUFA ratios, including (EPA+DHA)/AA, EPA/AA, DHA/AA, and DGLA/AA, and AF. Restricted cubic spline analyses revealed linear inverse associations for EPA, DHA, EPA+DHA, and AA and AF, whereas a nonlinear association for DGLA and AF was observed.</p><p><strong>Conclusion: </strong>Within the physiological ranges, higher plasma levels of EPA, DHA, EPA+DHA, AA, and DGLA were independently and inversely associated with AF risk. However, extremely high EPA concentrations, achieved through pharmacological interventions, have been suggested to be associated with an increased risk of AF.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"1140-1147"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracranial Arterial Stenosis beyond Atherosclerosis: Insights from RNF213.","authors":"Shuhei Okazaki","doi":"10.5551/jat.RV22053","DOIUrl":"10.5551/jat.RV22053","url":null,"abstract":"<p><p>Intracranial arterial stenosis is a major cause of ischemic stroke worldwide, particularly in the Asian population. Although traditionally regarded as a manifestation of atherosclerotic disease, increasing evidence suggests that non-atherosclerotic arteriopathies also contribute substantially to its pathogenesis. These conditions, including arterial dissection, inflammatory vasculopathies, and moyamoya disease, often share overlapping clinical and imaging features, thus making precise differentiation challenging in routine practice.This phenotypic overlap highlights the heterogeneity of intracranial arterial stenosis and suggests that it may represent a spectrum of vascular disorders, rather than a single disease entity. Recent studies have highlighted the role of genetic susceptibility as a factor underlying this diversity. Among these, RNF213, originally identified as a susceptibility gene for moyamoya disease, has been implicated in a subset of intracranial arterial diseases beyond the classical diagnostic categories. These observations have led to the concept of RNF213-related vasculopathy, which extends beyond intracranial circulation and provides a framework for understanding diverse vascular phenotypes within a broader context. In addition, a two-hit model has been proposed in which genetic susceptibility interacts with environmental and acquired factors to influence the disease onset and progression.This narrative review summarizes the current understanding of intracranial arterial stenosis beyond the conventional atherosclerosis-centered paradigm and discusses emerging concepts integrating vascular heterogeneity, genetic susceptibility, and environmental modifiers with potential implications for disease classification and individualized therapeutic strategies.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"1124-1131"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Application of Speckle-tracking Echocardiography in Atherosclerotic Cardiovascular Disease.","authors":"Koki Nakanishi","doi":"10.5551/jat.RV22060","DOIUrl":"https://doi.org/10.5551/jat.RV22060","url":null,"abstract":"<p><p>With aging societies, heart failure (HF) is a growing public health concern, particularly HF with a preserved left ventricular ejection fraction (HFpEF). Patients with atherosclerotic cardiovascular disease (ASCVD) are at an increased risk of incident HF, while the prediction of individual risk remains challenging. Speckle-tracking echocardiography enables an objective and quantitative assessment of subtle myocardial alterations that are undetectable with conventional echocardiography and has excellent feasibility and reproducibility. Left ventricular global longitudinal strain (LVGLS), a sensitive measure of LV systolic dysfunction, has been found to be an independent risk factor for the occurrence of HF. In addition, more than 50% of patients with HFpEF had impaired LVGLS. Recently, deformation imaging has been employed to assess left atrial (LA) performance, and impaired LA strain has been shown to predict unfavorable outcomes in various clinical settings. This review article presents the clinical relevance of subclinical left heart dysfunction in patients with ASCVD and describes its future perspectives.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The PCSK6-CORIN Polygenic Risk Score and Ischemic Stroke: The Dose-Response Association and Partial Mediation by Hypertension.","authors":"Zhengmei Fang, Tao Zhang, Lijun Zhu, Yuelong Jin, Yan Chen, Yingshui Yao","doi":"10.5551/jat.66291","DOIUrl":"https://doi.org/10.5551/jat.66291","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to assess the association of single nucleotide polymorphisms (SNPs) in the PCSK6‑CORIN pathway with IS, the predictive ability of weighted genetic risk score (wGRS), and the mediating role of hypertension.</p><p><strong>Methods: </strong>A total of 2,207 patients with IS and 2,590 community controls were included in this case-control study. The wGRS was developed using data from six TagSNPs in PCSK6 and CORIN. The associations, dose-response relationships, and mediation effects were assessed using logistic regression, restricted cubic spline, and mediation analyses.</p><p><strong>Results: </strong>Two SNPs (rs1135911 and rs4695253) were significantly associated with IS under the additive model: rs1135911 (OR=1.310, P_Bonferroni=1.28×10^-4) and rs4695253 (OR = 1.459, P_Bonferroni=3.17 × 10^-7). Negative multiplicative interactions were observed between rs3749585 and rs4695253/rs11934749 (OR = 0.625 and 0.548, respectively; both P＜0.001). The wGRS showed a linear dose-response relationship with IS (overall P＜0.001, nonlinear P = 0.907). Among the wGRS quartiles, the highest quartile had an OR of 1.653 and a P-value of 3.84×10^-7). The plasma CORIN levels were significantly lower in patients with IS than in the controls (973.60±589.37 pg/mL vs. 1197.85±848.46 pg/mL, P = 0.043) in 88 IS and 88 controls. A history of hypertension appeared to partially mediate the effect of wGRS on IS, with a mediation proportion of 9.4% (95% CI: 5.0%-15.7%).</p><p><strong>Conclusions: </strong>Genetic variants in the PCSK6‑CORIN pathway are associated with IS risk, and the genetic risk may be partially mediated by hypertension.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Triglyceride-High-density Lipoprotein Cholesterol Phenotypes and Cardiovascular Outcomes in Japanese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights from Clinical Deep Data Accumulation System-PCI.","authors":"Mitsukuni Kimura, Shunsuke Katsuki, Yasuhiro Nakano, Rissei Hino, Takuya Tabuchi, Genryu Mizokami, Keiji Oi, Mitsuhiro Fukata, Takanori Yamashita, Naoki Nakashima, Takahide Kohro, Tomoyuki Kabutoya, Kazuomi Kario, Yasushi Imai, Hideo Fujita, Naoyuki Akashi, Arihiro Kiyosue, Yoshiko Mizuno, Satoshi Kodera, Masaharu Nakayama, Kotaro Nochioka, Yoshihiro Miyamoto, Kenichi Tsujita, Masanobu Ishii, Hisahiko Sato, Kohtaro Abe, Tetsuya Matoba, Ryozo Nagai","doi":"10.5551/jat.66189","DOIUrl":"https://doi.org/10.5551/jat.66189","url":null,"abstract":"<p><strong>Aims: </strong>Despite intensive lipid-lowering therapy, residual cardiovascular risk remains prevalent among patients with coronary artery disease. Although triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) metabolism are closely interrelated, their combined prognostic significance in secondary prevention remains unclear.</p><p><strong>Methods: </strong>This study analyzed the Clinical Deep Data Accumulation System- Percutaneous Coronary Intervention (CLIDAS-PCI) database, a multicenter Japanese registry of patients with acute coronary syndrome undergoing PCI. Patients were stratified into four combined TG-HDL phenotypic groups using guideline-consistent cutoff values for high TG (≥ 175 mg/dL) and low HDL-C (≤ 40 mg/dL) levels. The primary outcome was a composite of major adverse cardiac and cerebrovascular events plus hospitalization for heart failure and its components.</p><p><strong>Results: </strong>Among 3,352 patients, high TG levels were not associated with the composite outcome but were consistently associated with an increased risk of recurrent myocardial infarction. Although low HDL-C levels were associated with increased cardiovascular risk, this association was attenuated after adjustment for renal function and nutritional status. Combined TG-HDL phenotyping revealed distinct risk profiles: patients with high TG and low HDL-C levels had the highest risk of recurrent myocardial infarction, while those with low TG and low HDL-C levels exhibited a markedly higher risk of cardiovascular death.</p><p><strong>Conclusions: </strong>In a Japanese secondary prevention cohort undergoing PCI, TG and HDLC demonstrated complementary and outcome-specific prognostic associations. Thus, combined TG-HDL phenotyping using guideline-based cutoffs may provide a simple and clinically relevant approach to stratifying residual cardiovascular risk beyond low-density lipoprotein cholesterol lowering.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Dyslipidemia in Ischemic Stroke: Pathophysiology, Clinical Evidence, and Future Perspectives.","authors":"Junya Aoki","doi":"10.5551/jat.RV22059","DOIUrl":"https://doi.org/10.5551/jat.RV22059","url":null,"abstract":"<p><p>Dyslipidemia is a major risk factor for atherosclerosis, and high low-density lipoprotein (LDL) cholesterol is closely associated with the onset of atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease. Numerous large-scale clinical trials have demonstrated that LDL cholesterol-lowering therapy, primarily involving statins, reduces not only coronary events, but also stroke, and has been established as a cornerstone of cardiovascular prevention. However, ischemic stroke is a group of diseases comprising different pathologies, such as atherothrombotic stroke, cardioembolic stroke, and small-vessel disease; the involvement of dyslipidemia and the efficacy of lipid-lowering therapy vary significantly depending on the subtype. Therefore, the evidence established for coronary artery disease cannot necessarily be applied directly to stroke management, and establishing lipid management strategies tailored to each subtype has become a critical challenge in stroke management. Furthermore, in recent years, in addition to LDL cholesterol-lowering therapy, treatments targeting hypertriglyceridemia, lipoprotein(a) [Lp(a)], and residual inflammatory risk have advanced, and the development of new therapeutic agents-such as PCSK9 inhibitors, selective PPARα modulators, and ATP citrate lyase inhibitors-is progressing, thus raising expectations for their application in stroke prevention. This article provides an overview of domestic and international guidelines for dyslipidemia and summarizes the association between dyslipidemia and ischemic stroke from the perspectives of pathophysiology, pathological findings, and imaging and blood biomarker. In addition, it outlines the latest evidence from large-scale clinical trials, new lipid-lowering therapies, acute-phase lipid management, and interventions targeting residual risk, and discusses the current status and future prospects of lipid management tailored to specific stroke subtypes.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of VEGF-C and VEGF-D in Coronary Artery Disease: From Molecular Pathophysiology to Therapeutic Lymphangiogenesis.","authors":"Hiromichi Wada, Kazuhiko Kotani, Moritake Iguchi, Koji Hasegawa","doi":"10.5551/jat.RV22058","DOIUrl":"https://doi.org/10.5551/jat.RV22058","url":null,"abstract":"<p><p>Traditional therapeutic strategies for coronary artery disease (CAD) primarily focus on arterial perfusion, largely overlooking the critical role of the cardiac lymphatic system in maintaining myocardial fluid, lipid, and immune homeostasis. The vascular endothelial growth factor C (VEGF-C) and VEGF-D/VEGF receptor-3 (VEGFR3) signaling axes are the primary drivers of lymphangiogenesis. However, recent clinical and mechanistic insights suggest that these two homologous ligands exert highly distinct and divergent pathophysiological roles under ischemic stress. This review synthesizes the current clinical, epidemiological, and preclinical evidence evaluating the distinct temporal and spatial dynamics of the VEGF-C/D axis. Large-scale clinical cohorts have revealed a striking prognostic divergence: while elevated circulating VEGF-D levels independently predict incident heart failure, atrial fibrillation, and mortality, low serum VEGF-C levels independently predict mortality. Mechanistically, adventitial lymphatics actively govern scavenger receptor class B type I (SR-BI)-dependent reverse cholesterol transport and macrophage trafficking. Preclinical large animal validation and phase 1/2 clinical trials (such as KAT301 and ReGenHeart) have demonstrated that timely, localized pro-lymphangiogenic interventions-leveraging modified mRNA, lipid nanoparticles, or sequential growth factor delivery kinetics-effectively resolve myocardial edema, suppress adverse remodeling, and improve the myocardial perfusion reserve. In conclusion, VEGF-C and VEGF-D represent a complex molecular dualism in CAD. Transitioning from non-specific growth factor overproduction to cell-specific, sequentially timed lymphatic therapeutics is a new frontier in halting the progression of adverse ventricular remodeling and chronic heart failure.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory Transcriptomic Profiling of Vein Tissue from Diabetic Patients Undergoing Arteriovenous Fistula Creation for Hemodialysis.","authors":"Tomohiro Shirouzu, Jun-Ichiro Koga, Eisuke Katafuchi, Yoichiro Nagai, Ryota Suga, Kenya Sanada, Hiromichi Ueno, Kazutoshi Nakazono, Emi Hasegawa, Tetsu Miyamoto, Toshiyuki Nakayama, Masaharu Kataoka","doi":"10.5551/jat.66048","DOIUrl":"https://doi.org/10.5551/jat.66048","url":null,"abstract":"<p><strong>Aim: </strong>Arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis; however, its patency is limited, particularly in patients with diabetes mellitus (DM). This study aimed to obtain exploratory data on whether changes in the venous transcriptome are present at the time of AVF creation in patients with DM and whether these changes are related to the graft prognosis.</p><p><strong>Methods: </strong>We conducted prospective transcriptome analyses using venous samples obtained during AVF creation from 22 patients (12 with DM and 10 without DM). RNA sequencing was performed, and clinical outcomes, including primary patency, were tracked for one year.</p><p><strong>Results: </strong>AVF patency was significantly lower in the DM group (median patency: 134 vs. 365 days, p＜0.05). Transcriptome profiling identified 285 differentially expressed genes, including those related to extracellular matrix organization, mitochondrial electron transport, TGF-β signaling, and the unfolded protein response. A network analysis highlighted hub genes, including MRPL27, MRPL23, and MRPL1, as potential biomarkers. A Cox regression analysis identified genes associated with the AVF prognosis, including PER3, SERINC2, COMMD10, TTC4, FKBP2, FN3KRP, KIF24, SNX32, MOB3C, SUV39H1, and TIGD6. Notably, a high COMMD10 expression, a core component of the commander complex, was associated with a shortened patency in patients with DM.</p><p><strong>Conclusions: </strong>Our findings demonstrate that DM is associated with distinct transcriptomic alterations in the access veins at the time of AVF creation. This integrative approach provides novel insights into the molecular basis of DM-related AVF failure and the potential to identify novel therapeutic targets.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Lipoprotein (a) Levels in Japanese Children.","authors":"Kazushige Dobashi","doi":"10.5551/jat.ED313","DOIUrl":"https://doi.org/10.5551/jat.ED313","url":null,"abstract":"","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}